Get started
Author

Xavier Monzonís

Observed names: X. Monzonis, X. Monzonís, Xavier Monzonis
ORCID: 0000-0002-1615-1538
Observed ORCID: 0000-0002-1615-1538
OpenAlex ID: A5015026317
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
2024 · Alejandro Ríos-Hoyo, Xavier Monzonís, et al. · Frontiers in Pharmacology · 44
PDF
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage
2020 · David Conde-Estévez, Inés Monge-Escartín, et al. · Journal of Chemotherapy · 20
Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib
2019 · Xavier Monzonís, Edurne Arriola · Journal of Thoracic Oncology · 13
PDF
Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells
2023 · Mònica Gonzàlez-Farré, Joan Gibert, et al. · Human Pathology · 11
Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).
2026 · Ghassan K. Abou-Alfa, Zhenggang Ren, et al. · Journal of Clinical Oncology · 7
PDF
A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer
2025 · C. Prieto-de-la-Lastra, J.A. Carbonell-Asins, et al. · ESMO Open · 5
PDF
Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al. · Clinical Cancer Research · 2
Supplementary Figure S2 from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al.
Supplementary Figure S4 from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al.
Supplementary Figure S3 from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al.
Supplementary Figure S5 from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al.
Data from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al.
Supplementary Table S1 from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al.
Supplementary Figure S1 from Next-Generation Sequencing of Circulating Tumor DNA for Precision Medicine in Patients with Advanced Biliary Tract Cancers
2026 · Laura Visa, Jordi Badia-Ramentol, et al.
975P Impact of body mass index on the efficacy of immune checkpoint inhibitors in cancer
2021 · A. Rios Hoyo, M. Hardy-Werbin, et al. · Annals of Oncology
PDF
Abstract 423: Pooled analysis of matching score and patient outcome in I-PREDICT and WINTHER studies
2021 · David Casadevall, Michal Marczyk, et al. · Cancer Research
186P Oncologists’ agreement on adjuvant therapy recommendations and the need of 21-gene recurrence score assay in HR+/HER2- early breast cancer
2020 · M. Castro-Henriques, D. Casadevall Aguilar, et al. · Annals of Oncology
Works count: 17
Citation count: 102
H-index: 5
I10-index: 4
Year
Topic
Type